Novartis

Novartis AG, a Swiss pharmaceutical company, reported its total carbon emissions for 2025 as approximately 4.38 billion kg CO2e. This includes Scope 1 emissions of about 192.3 million kg CO2e, Scope 2 market-based emissions of approximately 14.9 million kg CO2e, and Scope 3 emissions of around 4.17 billion kg CO2e.

Looking back, in 2024, Novartis's total emissions were approximately 4.52 billion kg CO2e. This comprised Scope 1 emissions of around 210.6 million kg CO2e, Scope 2 market-based emissions of approximately 29.8 million kg CO2e, and Scope 3 emissions of about 4.28 billion kg CO2e. In 2023, the total emissions were roughly 4.87 billion kg CO2e, with Scope 1 at about 251.1 million kg CO2e, Scope 2 market-based at approximately 44.1 million kg CO2e, and Scope 3 at around 4.57 billion kg CO2e.

Novartis is committed to significant climate action, aiming to achieve net-zero greenhouse gas emissions across its value chain by 2040. This commitment includes several near-term and long-term targets:

Near-Term Targets:

• Carbon Neutrality in Own Operations: Novartis aims to become carbon neutral in its own operations (Scope 1 and 2) by 2025.
• Emissions Reduction by 2030 (from 2022 baseline): The company plans to reduce absolute Scope 1 and 2 GHG emissions by 90%, and absolute Scope 3 GHG emissions by 42%.
• Emissions Reduction by 2030 (from 2016 baseline - SBTi): Novartis has a Science Based Targets initiative (SBTi) commitment to reduce absolute Scope 1, 2, and 3 GHG emissions by 35% by 2030 from a 2016 base year.

Long-Term Targets:

• Net-Zero by 2040: Novartis is committed to reaching net-zero greenhouse gas emissions across its entire value chain by 2040. This involves maintaining a minimum of 90% absolute Scope 1 and 2 emissions reductions from 2030 through 2040 (from a 2022 base year) and reducing absolute Scope 3 GHG emissions by 90% by 2040 (from a 2022 base year).

The company has also reported progress, with a 63% reduction in Scope 1 and 2 emissions (from energy) compared to its 2016 baseline by 2023. These reduction targets and achievements demonstrate Novartis's dedication to mitigating its environmental impact within the Pharmaceutical Preparation Manufacturing industry. All climate commitments and emissions data are reported by Novartis AG itself and are not cascaded from a parent organization.